Back to Authors

Schak, Kathryn M.

https://orcid.org/0000-0002-4726-3380

Mayo Clinic

Mayo Clinic

Citations 13

Reply to: Comment on: Aripiprazole-Associated Hiccups: A Case and Closer Look at the Association Between Hiccups and Antipsychotics
Silverman, Melissa, Leung, Jonathan G. , Schak, Kathryn M. , Silverman, Melissa A, Leung, Jonathan G

Journal of Pharmacy Practice | April 12, 2015 | Volume: 28 | Issue: 2 | Pages: 134-134

10.1177/0897190014568680 Get It

Aripiprazole-Associated Hiccups
Silverman, Melissa, Leung, Jonathan G. , Schak, Kathryn M. , Silverman, Melissa A, Leung, Jonathan G

Journal of Pharmacy Practice | August 9, 2014 | Volume: 27 | Issue: 6 | Pages: 587-590

10.1177/0897190014544797 Get It

Aripiprazole’s pharmacologic properties (including dopamine 2 and 5-hydroxytryptamine 1A [5HT1A] receptor partial agonism and 5HT2A receptors antagonism) may be associated with the onset of hiccups. Case Description: A 21-year-old, antipsychotic-naive patient with bipolar I disorder and remote brain trauma developed persistent hiccups following aripiprazole titration. Despite trials of metoclopramide and chlorpromazine, hiccups continued. Remission of hiccups occurred with discontinuation of aripiprazole. Discussion: The exact etiology of hiccups is unknown but likely involves dopamine and/or γ-butyric acid. Highlighting the uncertainty related to drug-induced hiccups is the fact that multiple antipsychotics have been reported to not only induce hiccups but also to alleviate them. As the development of persistent hiccups may result in extensive medical workup, clinicians should be aware of drug-associated causes including aripiprazole.
Serial infusions of low-dose ketamine for major depression
Rasmussen, Keith G., Lineberry, Timothy W., Galardy, Christine W., Kung, Simon , Palmer, Brian A. , Ritter, Matthew J. , Schak, Kathryn M. , Sola, Christopher L., Hanson, Allison J, Frye, Mark A. , Lapid, Maria I.

Journal of Psychopharmacology | February 21, 2013 | Volume: 27 | Issue: 5 | Pages: 444-450

10.1177/0269881113478283 Get It

Background: Single infusions of ketamine have been used successfully to achieve improvement in depressed patients. Side effects during the infusions have been common. It is not known whether serial infusions or lower infusion rates result in greater efficacy. Methods: Ten depressed patients were treated with twice weekly ketamine infusions of ketamine 0.5 mg/kg administered over 100 min until either remission was achieved or four infusions were given. Side effects were assessed with the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS). Patients were followed naturalistically at weekly intervals for four weeks after completion of the infusions. Results: Five of 10 patients achieved remission status. There were no significant increases on the BPRS or YMRS. Two of the remitting patients sustained their improvement throughout the four week follow-up period. Conclusions: Ketamine infusions at a lower rate than previously reported have demonstrated similar efficacy and excellent tolerability and may be more practically available for routine clinical care. Serial ketamine infusions appear to be more effective than a single infusion. Further research to test relapse prevention strategies with continuation ketamine infusions is indicated.